BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...
BC Extra | Jan 22, 2020
Company News

JV to combine technologies into one gene and cell therapy manufacturing platform

Two manufacturing deals Tuesday underscore manufacturing's vital role in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, will combine the partners' scalable technologies...
BC Innovations | Apr 25, 2019
Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
BC Innovations | Feb 28, 2019
Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
BC Week In Review | Jun 29, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Jun 26, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Apr 25, 2018
Company News

Management tracks: Urovant, Cue

Urology company Urovant Sciences, a subsidiary of Roivant Sciences GmbH (Basel, Switzerland), hired Cornelia Haag-Molkenteller as CMO, Michael McFadden as chief commercial officer, Bryan Smith as general counsel and Christine Ocampo as SVP and chief...
BC Week In Review | Nov 2, 2017
Company News

Bio-Techne acquires Trevigen

In September, Bio-Techne Corp. (NASDAQ:TECH) acquired fellow supply and service company Trevigen Inc. (Gaithersburg, Md.) for $11 million in cash. Trevigen specializes in reagents, kits and cell cultures to study programmed cell death and DNA...
BioCentury | Apr 29, 2017
Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
BioCentury | Feb 4, 2017
Finance

Earnings on deck

Earnings on deck At least 10 biotechs and pharmas are expected to report earnings the week of Feb. 6. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q Company Date Pre/post mkt 4Q16 EPS est...
Items per page:
1 - 10 of 34
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

Manufacturing remains a major hurdle for companies pursuing gene and cell therapies, and as more products make it to market, the bottleneck could create problems with commercial supply. At least seven manufacturing deals and site...
BC Extra | Jan 22, 2020
Company News

JV to combine technologies into one gene and cell therapy manufacturing platform

Two manufacturing deals Tuesday underscore manufacturing's vital role in the development of next-generation gene and cell therapies. The first, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf, will combine the partners' scalable technologies...
BC Innovations | Apr 25, 2019
Emerging Company Profile

miR Scientific: spotting aggression with RNA in urine

miR has paired its panel of urine-based RNAs with a statistical algorithm for accurate diagnosis of aggressive bladder and prostate cancers, sparing patients with lower-grade tumors from invasive biopsies and unnecessary drug treatments. The company's...
BC Innovations | Feb 28, 2019
Distillery Therapeutics

Inflammation

INDICATION: Inflammation Cell culture and mouse studies suggest IL-37 could help treat inflammation. In mouse macrophages treated with lipopolysaccharide (LPS), transgenic expression of human IL-37 decreased inflammatory cytokine levels compared with no transgene expression. In...
BC Week In Review | Jun 29, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Jun 26, 2018
Company News

Bio-Techne acquiring Exosome Diagnostics for $250M

Research supplier Bio-Techne Corp. (NASDAQ:TECH) will acquire cancer diagnostic company Exosome Diagnostics Inc. (Waltham, Mass.) for $250 million in cash. Exosome shareholders will also be eligible for $325 million in milestones based on future earnings...
BC Extra | Apr 25, 2018
Company News

Management tracks: Urovant, Cue

Urology company Urovant Sciences, a subsidiary of Roivant Sciences GmbH (Basel, Switzerland), hired Cornelia Haag-Molkenteller as CMO, Michael McFadden as chief commercial officer, Bryan Smith as general counsel and Christine Ocampo as SVP and chief...
BC Week In Review | Nov 2, 2017
Company News

Bio-Techne acquires Trevigen

In September, Bio-Techne Corp. (NASDAQ:TECH) acquired fellow supply and service company Trevigen Inc. (Gaithersburg, Md.) for $11 million in cash. Trevigen specializes in reagents, kits and cell cultures to study programmed cell death and DNA...
BioCentury | Apr 29, 2017
Finance

Earnings on deck

Earnings on deck At least 19 biotechs and pharmas are expected to report earnings this week. (A) Fiscal 2Q; (B) Fiscal 3Q Company Date Pre/post mkt 1Q17 EPS est 1Q16 EPS Expected chg Luminex Corp....
BioCentury | Feb 4, 2017
Finance

Earnings on deck

Earnings on deck At least 10 biotechs and pharmas are expected to report earnings the week of Feb. 6. (A) Fiscal 3Q; (B) Nine-month EPS; (C) Fiscal 2Q Company Date Pre/post mkt 4Q16 EPS est...
Items per page:
1 - 10 of 34